Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | HTT | P42858 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | PRNP | P04156 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | CASP7 | P55210 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064912 | 1.00 | CTSB (0.55) | CTSBHKDC1CASP6MAPTGAA | |
| SCHEMBL11232707 | 0.83 | CTSB (0.44) | CTSBHKDC1CASP6MAPTGAA | |
| SCHEMBL11672934 | 0.83 | CTSB (0.53) | CTSBHKDC1CASP6MAPTGAA | |
| SCHEMBL20788050 | 0.79 | CTSB (0.50) | CTSBHKDC1CASP6MAPTGAA | |
| SCHEMBL31365423 | 0.79 | CTSB (0.50) | CTSBHKDC1CASP6MAPTGAA | |
| SCHEMBL10063601 | 0.79 | CTSB (0.50) | CTSBHKDC1CASP6MAPTGAA | |
| SCHEMBL31504733 | 0.79 | CTSB (0.50) | CTSBHKDC1CASP6MAPTGAA | |
| SCHEMBL11796322 | 0.79 | CTSB (0.42) | CTSBHKDC1CASP6MAPTGAA | |
| SCHEMBL9990219 | 0.79 | EP300 (0.48) | CTSBHKDC1MAPTEP300SMN1; SMN2 | |
| SCHEMBL3267567 | 0.79 | CTSB (0.42) | CTSBHKDC1CASP6MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118265737-A | Triarylamine high molecular weight compound and organic electroluminescent element | 保土谷化学工业株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-11932633-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2008030226-A1 | 3H-NAPHTH0 [2, 1-B] PYRANS AS PHOTOCHROMIC DICHROIC DYES AND OPTICAL ARTICLE CONTAINING THEM | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008028930-A1 | 6-(BIPHENYL-ESTER)-3H-NAPHTHO[2, 1-B]PYRANS AS PHOTOCHROMIC DICHROIC DYES AND OPTICAL ARTICLE CONTAINING THEM | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008029194-A1 | 6-(BIPHENYL-ESTER) -3H-NAPHTHO [2, 1-B] PYRANS AS PHOTOCHROMIC DICHROIC DYES AND OPTICAL ARTICLE CONTAINING THEM | Essilor International (Compagnie Générale d'Optique) (FR) | 2008-03-13 | — | — | WO | disclosed |
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIAN PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7268232-B2 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-11 | — | — | US | disclosed |
| WO-2007092391-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1756101-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | Acadia Pharmaceuticals Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005115361-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | NR5A1, AR, CYP17A1 | CTSB 2931/4885HKDC1 573/4885CASP6 3220/4885 |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | NR5A1, AR, ESRRA | CTSB 2995/4885HKDC1 471/4885CASP6 3424/4885 |
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | NR5A1, AR, CYP17A1 | CTSB 2931/4885HKDC1 573/4885CASP6 3220/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CTSB 1394/4885HKDC1 772/4885CASP6 3115/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | CTSB 1358/4885HKDC1 4054/4885CASP6 1899/4885 |
| US-11932633-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CTSB 1394/4885HKDC1 772/4885CASP6 3115/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CTSB 1394/4885HKDC1 772/4885CASP6 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.